CD146 Associates with Gp130 to Control a Macrophage Pro‐inflammatory Program That Regulates the Metabolic Response to Obesity. Issue 13 (8th March 2022)

• Record Type: Journal Article
• Authors: Duan, Hongxia; Jing, Lin; Xiang, Jianquan; Ju, Chenhui; Wu, Zhenzhen; Liu, Jingyu; Ma, Xinran; Chen, Xuehui; Liu, Zheng; Feng, Jing; Yan, Xiyun
• Is Part Of: Advanced science. Volume 9:Issue 13(2022)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2022-03-08
• Subjects: CD146 -- Gp130 -- macrophage polarization -- obesity; Science -- Periodicals; 505
• DOI: 10.1002/advs.202103719
• Languages: English
• ISSNs: 2198-3844

Abstract

Abstract: The mechanism of obesity‐related metabolic dysfunction involves the development of systemic inflammation, largely mediated by macrophages. Switching of M1‐like adipose tissue macrophages (ATMs) to M2‐like ATMs, a population of macrophages associated with weight loss and insulin sensitivity, is considered a viable therapeutic strategy for obesity‐related metabolic syndrome. However, mechanisms for reestablishing the polarization of ATMs remain elusive. This study demonstrates that CD146 + ATMs accumulate in adipose tissue during diet‐induced obesity and are associated with increased body weight, systemic inflammation, and obesity‐induced insulin resistance. Inactivating the macrophage CD146 gene or antibody targeting of CD146 alleviates obesity‐related chronic inflammation and metabolic dysfunction. Macrophage CD146 interacts with Glycoprotein 130 (Gp130), the common subunit of the receptor signaling complex for the interleukin‐6 family of cytokines. CD146/Gp130 interaction promotes pro‐inflammatory polarization of ATMs by activating JNK signaling and inhibiting the activation of STAT3, a transcription factor for M2‐like polarization. Disruption of their interaction by anti‐CD146 antibody or interleukin‐6 steers ATMs toward anti‐inflammatory polarization, thus attenuating obesity‐induced chronic inflammation and metabolic dysfunction in mice. The results suggest that macrophage CD146 is an important determinant of pro‐inflammatory polarization and plays a pivotal role in obesity‐induced metabolic dysfunction. CD146 could constitute a novel therapeutic target for obesity complications. Abstract : Under hyperlipidemia conditions, CD146 interacts with Gp130 to inhibit ACM (mainly IL‐6)‐induced STAT3 activation. It also activates the JNK signal and promotes the expression of M1‐related genes and SOCS3, which enhances the STAT3 inhibition. Deletion or blocking CD146 steers ATMs toward anti‐inflammatory polarization, thus attenuating obesity‐induced chronic inflammation and metabolic dysfunction.